Abstracts tagged "Lupus nephritis"

Abstract Number: 0784 • ACR Convergence 2023
Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial
Brad Rovin¹, Jorge Ross Terres², Sophia Giang³, Thomas Schindler⁴, Armando Turchetta⁵, Jay Garg², Richard Furie⁶, William F. Pendergraft III² and Ana Malvar⁷, ¹Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Genentech, Inc., San Francisco, CA, ⁴F. Hoffmann-La Roche Ltd, Basle, Switzerland, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁶Northwell Health, Manhasset, NY, ⁷Hospital Fernandez, Buenos Aires, Argentina
Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…
Abstract Number: 0923 • ACR Convergence 2023
Identification of Lupus Nephritis Kidney Immune Populations via Hi-Resolution 20-Plex Immunohistochemistry Single-Cell Spatial Analyses
Caleb Marlin¹, Alessandra Ida Celia², Richard Furie³, Judith James¹, Andrea Fava⁴, Joel Guthridge¹, Avi Rosenberg⁵, Tayte Stephens¹, Christian Wright¹, Jeff Hodgin⁶, Peter Izmirly⁷, H Michael Belmont⁸, Jennifer Anolik⁹, Michelle Petri¹⁰, Jill Buyon¹¹, Diane L. Kamen¹², Chaim Putterman¹³, Accelerating Medicines Partnership in RA/SLE The¹, Chen-Yu Lee⁴ and Xiaoping Yang⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²John Hopkins University of Medicine, Rome, Italy, ³Northwell Health, Manhasset, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Michigan, Ann Arbor, MI, ⁷New York University School of Medicine, New York, NY, ⁸NYU School of Medicine, New York, NY, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹¹NYU Grossman School of Medicine, New York, NY, ¹²Medical University of South Carolina, Charleston, SC, ¹³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Immunohistochemistry is the gold standard for antibody staining in microscopy. However, a lack of multiplexing limits its utility in the use of discovery. Here…
Abstract Number: 1490 • ACR Convergence 2023
Early Experience with SGLT2i in Systemic Lupus Erythematosus
Michelle Petri¹, Daniel Goldman¹, Andrea Fava² and Larry Magder³, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of the systemic lupus erythematosus (SLE) patients. It remains an independent risk factor for mortality, with deaths…
Abstract Number: 1698 • ACR Convergence 2023
High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis
Huihua Ding, Yiwei Shen, Min Dai and Nan Shen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Navigating the molecular complexity of lupus nephritis (LN), a heterogeneous autoimmune disorder, poses challenges to biomarker discovery. This study addresses these challenges through an…
Abstract Number: 2427 • ACR Convergence 2023
Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis
Alessandra Ida Celia¹, Xiaoping Yang², Hana Minsky², Silvia Malvica², Michelle Petri³, the Accelerating Medicines Partnership in RA/SLE⁴, Avi Rosenberg⁵ and Andrea Fava², ¹John Hopkins University of Medicine, Rome, Italy, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴Multiple, Multiple, ⁵Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: As part of the Accelerating Medicines Partnership (AMP), we discovered that urinary PR3, a neutrophil degranulation product, is associated with histological activity, indicating the…
Abstract Number: 0125 • ACR Convergence 2023
Decreasing Ischemic Heart Disease, but Increasing Cancer Among the Underlying Causes of Death in Decedents with Lupus Nephritis
snehin Rajkumar¹ and Ram Singh², ¹University of California Los Angeles, Irvine, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Patients with lupus nephritis may die of active systemic lupus erythematosus (SLE) disease, end-stage renal disease (ESRD) and its complications as well as of…
Abstract Number: 0786 • ACR Convergence 2023
A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort
Anna Arar, Diane L. Kamen, Paul Nietert and Melissa Cunningham, Medical University of South Carolina, Charleston, SC
Background/Purpose: Manifestations of systemic lupus erythematous (SLE) vary in severity and presentation; lupus nephritis (LN) affects up to half of SLE patients and confers a…
Abstract Number: 0930 • ACR Convergence 2023
Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage
Aastha Khatiwada¹, bethany wolf², Isabelle Ayoub³, Juan Mejia-Vilet⁴, Ana Malvar⁵, Carl Langefeld⁶, Brad Rovin³, Jim Oates² and Betty Tsao², ¹National Jewish Health, Denver, CO, ²Medical University of South Carolina, Charleston, SC, ³Ohio State University, Columbus, OH, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Hospital Fernandez, Buenos Aires, Argentina, ⁶Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Many genetic variants are associated with lupus nephritis (LN). Yet, the majority of associated variants have a small effect size; hence, they convey small…
Abstract Number: 1493 • ACR Convergence 2023
Novel BCMA-CD19 Compound CAR-T (cCAR) Targets B Cells and Plasma Cells Achieving Immune Reset and Eliminates All Autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients Resulting in Long-Term, Medication-Free Remission
Yong Yuan¹, Shanzhi He¹, Wenli Zhang², Hongyu Zhang², Vincent DeStefano³, Masayuki Wada³, Kevin Pinz³, Greg Deener³, Yu Ma⁴, Min Wang¹, Fugui Li¹, Ming Hong¹, Chanjuan Zou¹, Mingxia Wang¹, Ling Ding¹, Yingwen Liang¹, Yupo Ma³ and Weijia Wang¹, ¹Zhongshan People’s Hospital, Zhongshan, China, ²Peking University Shenzhen Hospital, Shenzhen, China, ³iCell Gene Therapeutics Inc., Stony Brook, NY, ⁴iCAR Bio Therapeutics Ltd, Zhongshan, China
Background/Purpose: Evaluate cCAR safety in SLE, LN and autoimmune conditions. Determine whether a single dose eliminates autoantibodies with well tolerated long-term, medication-free remission in open…
Abstract Number: 1705 • ACR Convergence 2023
Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Betsy Barnes¹, Lydia Thomas², Jenna Battaglia Battaglia³, Kim Simpfendorfer³, Joyce Hui-Yuen⁴, Vinay Sharma⁵ and Bharati Matta⁶, ¹Northwell Health, Manhasset, NY, ²Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ³Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁴North Shore LIJ Health System, Great Neck, NY, ⁵Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India, ⁶The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY and Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, NY
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a multisystemic chronic autoimmune disease with high renal involvement. In SLE, neutrophil extracellular traps (NETs) are considered a…
Abstract Number: 2443 • ACR Convergence 2023
Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus
Junpeng Zhao¹, Liming Li¹, Xiwei Feng¹, Huiqi Yin¹ and Qianjin Lu², ¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, ²Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Changsha, China
Background/Purpose: Genetic variations in the OX40 ligand (OX40L) locus have been implicated in the susceptibility to systemic lupus erythematosus (SLE). Notably, the blockade of OX40L…
Abstract Number: 0179 • ACR Convergence 2023
Social Disparities and Pathology Markers at Lupus Nephritis Diagnosis Predict Worse Kidney Outcomes
Shivani Garg¹, Brad Astor², Amish Raval², S. Sam Lim³, Weixiong Zhong², Sarah Panzer², Brad Rovin⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³Emory University, Atlanta, GA, ⁴Ohio State University, Columbus, OH
Background/Purpose: At diagnosis, a typical 30-year-old with lupus nephritis (LN) already has 10-fold higher chronic kidney disease (CKD) risk than peers and LN is a…
Abstract Number: 0849 • ACR Convergence 2023
Multiplex Profiling and Machine Learning Reveal Distinct Signatures of Circulating Cytokines Associated with Autoantibody Profiles and Disease Severity in Systemic Lupus Erythematosus
Sarit Pattanaik¹, Ratnadeep Mukherjee², Rina Tripathy³, Birendra Prusty⁴, Balachandran Ravindran⁵ and Bidyut Das⁶, ¹SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, India, ²Norwegian Institute of Public Health, Oslo, Norway, ³Sardar Vallabhbhai Patel Post Graduate Institute of Pediatrics, Cuttack, India, ⁴Fisheries & Animal Resources Development Department, Phulbani, India, ⁵Institute of Life Sciences, Bhubaneswar, India, ⁶SCB medical college, Cuttack, India
Background/Purpose: SLE is one of the leading causes of death in young females suffering from autoimmune disorders. Nephritis, afflicts 60-70% of patients which contribute significantly…
Abstract Number: 0933 • ACR Convergence 2023
The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis
Rhea Bhargava¹, Rohit Upadhyay², Scott Wenderfer³, Jing Chen² and George Tsokos⁴, ¹Tulane University, New Orleans, LA, ²Tulane University School of Medicine, New Orleans, LA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis (LN) occurs in 50% of patients with systemic lupus erythematosus (SLE) for which we lack biomarkers, and an understanding of its pathogenesis.…
Abstract Number: 1495 • ACR Convergence 2023
Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells
Samik Basu¹, Daniel Nunez¹, Darshil Patel¹, Jenell Volkov¹, Zachary Vorndran¹, Steven Wong¹, Andreas Mackensen² and Georg Schett³, ¹Cabaletta Bio, Philadelphia, PA, ²Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a ground-breaking emerging treatment modality for severe refractory systemic lupus erythematosus (SLE) and has shown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].